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Open Forum Infectious Diseases
MAJOR ARTICLE

Coinfections in Patients With Cancer and COVID-19: A
COVID-19 and Cancer Consortium (CCC19) Study
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Background. The frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection.
Methods. We included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratoryconfirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer
Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors
cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality.
Results. Among 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1%
bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection
was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic
malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab
administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial
coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher
among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33–1.95) and fungal (OR, 2.20; 95% CI, 1.28–3.76) coinfections.
Conclusions. Viral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated
with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which
may improve clinical outcomes.
Keywords. bacterial infections; CAPA (COVID-19-associated pulmonary aspergillosis); COVID-19; mucormycoses; viral
infections.
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Severe acute respiratory syndrome coronavirus 2 (SARSCOV-2), the etiologic agent of coronavirus disease 2019
(COVID-19), has infected >288 million people and contributed to >5.4 million deaths globally [1]. Among patients with
confirmed COVID-19, the frequency of cancer diagnosis has
been reported to be 2% [2]. Nevertheless, large meta-analyses of
patients with cancer and COVID-19 have described mortality
rates of 19%–23% and a case fatality rate (CFR) of 23% [2, 3].
Conversely, patients without cancer with COVID-19 had 3-fold
lower odds of mortality and a CFR of only 6% [2, 3]. Patients
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METHODS
Study Design

The COVID-19 and Cancer Consortium (CCC19) is an international registry that includes reports of >12 000 patients with
current or historical cancer diagnoses who developed presumed
or laboratory-confirmed COVID-19. The registry was built by
and is maintained at Vanderbilt University Medical Center
(VUMC) [10]. One hundred twenty-nine participating sites
from the United States, Mexico, and Canada independently
identify patients and report data through electronic REDCap
survey instruments developed by CCC19. The mechanism of
data collection can be retrospective (after the course of COVID19) or concurrent at the discretion of the respondent. To ensure
that data are high quality, each report is reviewed centrally and
assigned a quality score, as previously described [10].
This was a retrospective cohort study with cross-sectional
analyses (except for mortality analysis). We included adult
(≥18 years) patients with a laboratory-confirmed diagnosis of
SARS-CoV-2 infection, regardless of hospitalization status. We
excluded reports with inadequate data quality (>4 according to
our previously published metric), those with noninvasive cancers, premalignant conditions, nonmelanoma skin cancers, and
2 • OFID • Satyanarayana et al

those with unknown coinfection status or 30-day mortality [10].
Patients who were not admitted to the hospital were excluded
from analyses that included laboratory values, because laboratory values were uncommonly reported among outpatients.
Procedures and Outcome Definitions

Day of COVID-19 diagnosis (baseline) was defined as the
day the first positive PCR test was collected. The primary end
point was any non-SARS-CoV-2 infection diagnosed with positive microbiological tests and/or compatible clinical picture
(eg, chest imaging with superimposed pneumonia, not due
to COVID-19 alone per clinician assessment), as explained
below. All coinfections studied within this cohort were reported to have been within ±2 weeks of COVID-19 diagnosis.
Coinfection data were either reported via a structured data field
or interpreted from de-identified free-text responses provided
by sites for each patient at the time of data entry, with queries
sent to individual sites for clarification when appropriate (full
data dictionary available at: https://github.com/covidncancer/
CCC19_dictionary).
Secondary end points were bacterial, viral, and fungal
coinfections. In a separate outcome analysis, we evaluated the
association between coinfection and all-cause mortality within
30-days after COVID-19 diagnosis.
Covariates

Clinically relevant variables included in this study were age,
sex, race and ethnicity, time of COVID-19 diagnosis, geographical region of patient residence, smoking status, obesity,
comorbid conditions (cardiovascular, pulmonary, renal disease, diabetes), Eastern Cooperative Oncology Group (ECOG)
Performance Status, type of malignancy (solid or hematological), cancer status (remission or active [measurable] disease,
with active further classified as stable, responding to treatment,
or progressing), anticancer therapy, and COVID-19 treatments.
Active anticancer therapy was classified as either cytotoxic chemotherapy or all other therapies except surgery (targeted drugs,
endocrine therapy, immunotherapy, radiotherapy) given before
COVID-19 diagnosis [10].
We could not determine whether corticosteroids initiated
after diagnosis of COVID-19 for treatment of COVID-19 were
administered before or after coinfection onset. Therefore, we
only studied baseline corticosteroids (preceding COVID-19 diagnosis, which the patients were taking for reasons other than
COVID-19). Nevertheless, we examined the cross-sectional association between tocilizumab use as treatment for COVID-19
and superinfections, given that active infection is a contraindication to tocilizumab administration [11]. Therefore, it is highly
unlikely that tocilizumab was administered after diagnosis of
an infection other than COVID-19, and any coinfections were
in all likelihood diagnosed after administration of tocilizumab.
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with cancer hospitalized for management of COVID-19 have
a >40% risk of developing severe illness [2].
Critical illness with interventions such as the placement of
central venous access catheters and endotracheal tubes and
shifts in the immune profile during COVID-19 might lead to
the development of a coinfection [4]. Treatment modalities for
COVID-19, including steroids and other immune-modulating
therapies, such as interleukin 6 (IL6) inhibitors (eg, tocilizumab),
can increase the risk of development of secondary infections.
Several studies have described coinfections among patients with
COVID-19. Meta-analyses have found bacterial infection rates
of 3.5%–7% on initial presentation and 14.3% for secondary bacterial infection [5, 6]. A systematic review of 9 studies reporting
coinfections among patients with COVID-19 showed that 8% of
patients developed a bacterial or fungal coinfection [7].
Patients with cancer are vulnerable to infection due to
myelosuppression and other forms of direct immune suppression
caused by cytotoxic chemotherapy or chronic steroids, side effects of chemotherapy on mechanical barriers (eg, mucositis and
skin ulceration), presence of indwelling central venous catheters,
and increased exposure to health care facilities [8]. One study of
684 patients with cancer focused on coinfections showed higher
incidence compared with the general population [5–7, 9].
In this study, we captured bacterial, fungal, and viral
coinfections in a large multi-institutional cohort of patients
with cancer and COVID-19, identified factors associated with
an increased risk of such coinfections, and quantified the association of coinfections with 30-day all-cause mortality.

Statistical Methods

Table 1. Baseline Demographic and Clinical Characteristics Stratified by
Diagnosis of any Coinfection
Any Coinfection
(n = 1459), No. (%)
Agea
Median [IQR], y

69.0 [60.0–78.0]

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or manuscript preparation. The corresponding author had full access to aggregate
data in the study and had final responsibility for the decision to
submit for publication.

64.0 [54.0–74.0]

Sex
Female

676 (46.3)

3925 (53.7)

Male

781 (53.5)

3376 (46.2)

Missing/unknown

2 (0.1)

5 (0.1)

Race/ethnicity
Non-Hispanic White

791 (54.2)

3866 (52.9)

Non-Hispanic Black

276 (18.9)

1340 (18.3)

Hispanic

232 (15.9)

1150 (15.7)

Other

144 (9.9)

827 (11.3)

16 (1.1)

123 (1.7)

Northeast

685 (46.9)

2465 (33.7)

Midwest

332 (22.8)

2033 (27.8)

South

177 (12.1)

1120 (15.3)

West

185 (12.7)

1393 (19.1)

Missing/unknown
Region

Undesignated

10 (0.7)

0 (0.0)

Non-US

70 (4.8)

295 (4.0)

Never smoked

688 (47.2)

3964 (54.3)

Former smoker

659 (45.2)

2693 (36.9)

Current smoker

54 (3.7)

438 (6.0)

Missing/unknown

58 (4.0)

211 (2.9)

No

932 (63.9)

4471 (61.2)

Yes

526 (36.1)

2796 (38.3)

1 (0.1)

39 (0.5)

Diabetes

502 (34.4)

1830 (25.0)

Pulmonary disease

376 (25.8)

1364 (18.7)

Cardiovascular disease

582 (39.9)

1956 (26.8)

Renal disease

320 (21.9)

942 (12.9)

Smoking status

Obesity

Missing/unknown
Comorbid conditionsb

Missing/unknown

4 (0.3)

62 (0.8)

ECOG Performance Status
0

310 (21.2)

2579 (35.3)

1

378 (25.9)

1871 (25.6)

2+

324 (22.2)

894 (12.2)

Unknown

445 (30.5)

1955 (26.8)

Missing

2 (0.1)

7 (0.1)

Type of malignancyb
Solid tumor

Role of the Funding Source

No Coinfection
(n = 7306), No. (%)

1113 (76.3)

5973 (81.8)

417 (28.6)

1567 (21.4)

Remission/NED

640 (43.9)

3522 (48.2)

Stable/responding

370 (25.4)

2218 (30.4)

Progressing

264 (18.1)

918 (12.6)

Unknown

185 (12.7)

645 (8.8)

Hematological neoplasm
Cancer status

Missing

0 (0.0)

3 (0.0)

HCT
No

1449 (99.3)

7267 (99.5)

RESULTS

Yes

10 (0.7)

38 (0.5)

0 (0.0)

1 (0.0)

Patient Cohort

Recent cytotoxic chemotherapy

Of 12 034 reports in the registry at the time of data lock
(6/6/2021), 8765 patients met inclusion criteria (Figure 1).

Never/beyond 12 mo

Missing/unknown

Within 4 wk

1015 (69.6)

5453 (74.6)

275 (18.8)

1129 (15.5)
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All analysis methods were prespecified in a statistical analysis
plan before initiation of the analysis (included with variable list
as Supplementary Data). We used descriptive statistics to compare baseline characteristics between patients with and without
any coinfection, both overall and among patients who were
hospitalized for any reason at the time of COVID-19 diagnosis.
Adjusted cross-sectional associations between these characteristics and the odds of any coinfection, as well as bacterial, viral,
and fungal coinfections, were estimated from multivariable logistic regression models and represented as odds ratios (ORs)
and 95% CIs. Logistic regression models also quantified the
adjusted association of coinfection (any, bacterial, viral, fungal,
and not classified [clinical only diagnosis]) with 30-day mortality. Adjustment variables were selected a priori based on clinical knowledge (Table 2; Supplementary Table 2); no statistical
model selection procedures were used.
Exploratory analyses with smoothing splines were used to
determine the association of age (as a continuous variable)
with outcomes; regression splines were used to model apparent
nonlinear associations. For analyses of any coinfection and
bacterial coinfections, there were sufficient degrees of freedom
to include all prespecified variables. For analyses of viral and
fungal coinfections, model degrees of freedom were limited
by the low number of events. We therefore used a reduced set
of variables considered to be most clinically relevant (Table 1;
Supplementary Table 1). Model stability was assessed by comparing adjusted and unadjusted regression coefficients and their
standard errors, as well as variance inflation factors.
Multiple imputation (10 iterations) using additive regression, bootstrapping, and predictive mean matching was used
to impute missing and unknown data, except unknown ECOG
Performance Status and unknown cancer status, which were not
imputed and included as “unknown” categories. Imputation was
performed on the full data set (n = 8765). A separate imputation
model (20 iterations) was developed for laboratory values among
hospitalized patients (n = 4508). All analyses were performed
in R, version 4.0.4 (R Foundation for Statistical Computing,
Vienna, Austria), including the rms extension package.

Table 1. Continued
No Coinfection
(n = 7306), No. (%)

4 wk to 3 mo

64 (4.4)

252 (3.4)

3 to 12 mo

40 (2.7)

247 (3.4)

Missing/unknown

65 (4.5)

225 (3.1)

No

1102 (75.5)

6152 (84.2)

Yes

325 (22.3)

1012 (13.9)

32 (2.2)

142 (1.9)

No

1326 (90.9)

6971 (95.4)

Yes

99 (6.8)

121 (1.7)

Missing/unknown

34 (2.3)

214 (2.9)

Baseline corticosteroids

Missing/unknown
Tocilizumab

Period of COVID-19 diagnosis
Jan–Apr 2020

385 (26.4)

1697 (23.2)

May–Aug 2020

689 (47.2)

2870 (39.3)

Sept–Dec 2020

226 (15.5)

1562 (21.4)

Jan–Apr 2021

142 (9.7)

1114 (15.2)

May–June 2021
Missing/unknown

11 (0.8)

45 (0.6)

6 (0.4)

18 (0.2)

Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology
Group; IQR, interquartile range; HCT, hematopoietic cell transplant; NED, no evidence of
disease.
a

Age was truncated at 90 years.

b

Percentages could sum to >100% because categories are not mutually exclusive.

The median age (interquartile range) was 65 (55–75) years;
47.4% were male, 53.1% were non-Hispanic White, 18.4% were
non-Hispanic Black, and 15.8% were Hispanic. Most patients
(80.8%) had solid tumors; 22.6% had hematologic malignancies; approximately half (51.4%) were hospitalized at the time of
COVID-19 diagnosis; 11.8% died within 30 days after diagnosis
of COVID-19. Patient characteristics are summarized in Table
1 for all patients and in Supplementary Table 1 for those who
were hospitalized.
Factors Associated With Coinfections

A total of 1459 patients (16.6%) developed any coinfection,
with 1059 (12.1%) bacterial, 188 (2.1%) viral, 79 (0.9%) fungal,
and 560 (6.4%) coinfections that were diagnosed clinically.
Adjusted cross-sectional associations of clinical or treatment
factors and coinfections are summarized in Table 2 and Figure
2 for all patients and in Supplementary Table 2 for hospitalized
patients only. Clinical types of coinfections are summarized in
Supplementary Table 3.
Risk of any coinfection was positively associated with age
among patients >50 years, male sex, cardiovascular, pulmonary,
or renal comorbid conditions, diabetes, ECOG Performance
Status, hematologic malignancy, multiple malignancies, progressing or unknown cancer status, cytotoxic chemotherapy
within 4 weeks before COVID-19 diagnosis, baseline corticosteroids, tocilizumab administration, and COVID-19 diagnosis
between May and August 2020.
4 • OFID • Satyanarayana et al

Mortality

All-cause 30-day mortality was significantly higher among patients with any (23.8%), bacterial (24.6%), and viral (22.9%)
coinfections compared with all other patients (9.4%, 10.1%, and
11.6%, respectively) and >2-fold higher among patients with
fungal coinfections (34.2%), compared with all other patients
(11.6%) (Figure 3). Adjusted 30-day all-cause mortality rates
were markedly higher among patients with any, bacterial, and
especially fungal coinfections, compared with those without the
respective coinfections (Table 3).
DISCUSSION

We identified factors associated with coinfection among 8765
patients with cancer and COVID-19. Laboratory values such as
high neutrophil count may be useful in differentiating bacterial or fungal coinfection from COVID-19 alone. Neutropenia
was associated with fungal coinfections, which were overall
rare. Development of any, but especially fungal coinfection, was
associated with higher adjusted all-cause mortality compared
with patients without coinfection. Tocilizumab administration
exhibited a strong association with development of bacterial
and fungal superinfection.
Infection remains a leading cause of mortality among immunocompromised patients, including those with malignancies
[8]. Many more patients with cancer die from infection, compared with the general population [12]. Patients with cancer and
COVID-19 are subject to immune modulation through treatments for cancer (eg, chemotherapy-induced myelosuppression,
administration of corticosteroids for antineoplastic or supportive purposes) and for COVID-19 infection (eg, corticosteroids, IL6 inhibitors). Furthermore, SARS-CoV-2 has been
implicated as an immunomodulating virus, causing a maladaptive immune response [4].
The percentage of coinfections in immunocompromised patients with COVID-19 has been previously reported to be as
high as 60% among transplant recipients [13]. In another recent study of patients with underlying malignancies or organ
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Any Coinfection
(n = 1459), No. (%)

A majority of the above factors showed strong associations of
similar magnitude with the risk of bacterial coinfections. The risk
for viral coinfection was positively associated with pulmonary
disease, diabetes, hematologic malignancy, multiple malignancies,
baseline corticosteroids, and diagnosis of COVID-19 between
May and August 2020. Fungal coinfections were associated with
cytotoxic chemotherapy last given between 3 months and 4 weeks
before COVID-19 diagnosis and tocilizumab administration.
Among hospitalized patients, high C-reactive protein (CRP)
was associated with higher risk of any coinfection, and high
neutrophil count was associated with higher risk of bacterial or
fungal coinfection. Neutropenia was associated with higher risk
of fungal coinfection. Lymphopenia was not associated with
risk of coinfection.

Table 2.

Adjusted Associations of Baseline Factors With Concomitant Infection Among all Patients
Any Coinfection Odds
Ratio (95% CI)

Bacterial Coinfection
Odds Ratio (95% CI)

Age

Viral Coinfection Odds
Ratio (95% CI)

Fungal Coinfection Odds
Ratio (95% CI)

0.94 (0.85–1.05)a

1.00 (0.85–1.18)a

≤50 (per decade increase)

1.02 (0.88–1.18)

0.99 (0.83–1.18)

-

-

>50 (per decade increase)

1.14 (1.07–1.21)

1.18 (1.10–1.27)

-

-

-

-

-

-

Sex
Female

Ref
1.23 (1.08–1.38)

Ref
1.21 (1.05–1.38)

Race/ethnicity
Non-Hispanic White

-

-

Non-Hispanic Black

0.97 (0.82–1.14)

Ref

1.02 (0.85–1.23)

Ref

-

-

Hispanic

1.09 (0.91–1.31)

1.29 (1.06–1.58)

-

-

Other

0.83 (0.67–1.03)

0.75 (0.58–0.97)

-

-

Ref

-

Region
Northeast

Ref

Ref

Midwest

0.68 (0.58–0.79)

0.92 (0.77–1.09)

0.40 (0.26–0.60)

-

South

0.71 (0.58–0.86)

0.86 (0.69–1.08)

0.26 (0.14–0.48)

-

West

0.60 (0.50–0.73)

0.92 (0.75–1.13)

0.34 (0.20–0.58)

-

Non-US

1.12 (0.82–1.53)

1.70 (1.21–2.39)

0.18 (0.04–0.72)

-

Smoking status
Never smoked

-

-

Former smoker

1.08 (0.95–1.23)

Ref

1.02 (0.88–1.18)

Ref

-

-

Current smoker

0.65 (0.48–0.89)

0.67 (0.47–0.96)

-

-

Obesity
No
Yes

Ref
0.97 (0.85–1.10)

Ref

Ref

1.04 (0.90–1.20)

0.87 (0.64–1.20)

Ref
0.67 (0.41–1.11)

Diabetes
No
Yes

Ref
1.35 (1.18–1.54)

Ref

Ref

1.36 (1.17–1.57)

1.51 (1.09–2.08)

Ref
1.16 (0.70–1.91)

Pulmonary disease
No
Yes

Ref
1.27 (1.10–1.47)

Ref

Ref

1.32 (1.12–1.55)

1.69 (1.22–2.35)

Ref
1.39 (0.83–2.33)

Cardiovascular disease
No
Yes

Ref
1.22 (1.06–1.40)

Ref
1.27 (1.09–1.48)

-

-

-

-

-

-

-

-

Renal disease
No
Yes

Ref
1.31 (1.12–1.53)

Ref
1.35 (1.14–1.61)

ECOG Performance Status
0

-

-

1

1.30 (1.10–1.55)

Ref

1.45 (1.19–1.76)

Ref

-

-

2+

1.95 (1.61–2.37)

2.33 (1.88–2.89)

-

-

Unknown

1.60 (1.36–1.90)

1.50 (1.23–1.82)

-

-

Type of malignancy
Solid tumor

Ref

Ref

Ref

Ref

Hematological neoplasm

1.41 (1.21–1.64)

1.39 (1.17–1.66)

1.85 (1.31–2.62)

1.57 (0.93–2.65)

Multiple tumors

1.34 (1.12–1.59)

1.40 (1.16–1.70)

1.60 (1.05–2.42)

1.27 (0.65–2.49)

Cancer status
Remission/NED

-

-

Stable/responding

0.78 (0.67–0.91)

Ref

0.80 (0.67–0.95)

Ref

-

-

Progressing

1.26 (1.05–1.51)

1.13 (0.92–1.40)

-

-

Unknown

1.25 (1.03–1.53)

1.13 (0.90–1.43)

-

-

Ref

-

HCT
No
Yes

Ref
1.22 (0.58–2.57)

Ref
1.18 (0.50–2.75)

1.66 (0.37–7.37)

-

Recent cytotoxic chemotherapy
Never/beyond 12 mo
Within 4 wk

Ref
1.35 (1.13–1.60)

Ref

Ref

1.16 (0.95–1.42)

0.89 (0.60–1.31)

Ref
1.54 (0.86–2.74)
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Table 2. Continued
Any Coinfection Odds
Ratio (95% CI)

Bacterial Coinfection
Odds Ratio (95% CI)

Viral Coinfection Odds
Ratio (95% CI)

Fungal Coinfection Odds
Ratio (95% CI)

4 wk to 3 mo

1.28 (0.94–1.73)

1.19 (0.84–1.69)

0.79 (0.37–1.66)

3.08 (1.41–6.70)

3 to 12 mo

0.90 (0.62–1.29)

0.75 (0.49–1.16)

0.55 (0.20–1.54)

0.93 (0.21–4.03)

Baseline corticosteroids
No
Yes

Ref
1.39 (1.19–1.62)

Ref

Ref

1.23 (1.02–1.47)

2.42 (1.75–3.35)

Ref
1.40 (0.82–2.40)

No
Yes

Ref
3.32 (2.48–4.44)

Ref

Ref

3.61 (2.67–4.87)

1.78 (0.98–3.21)

Ref
5.48 (2.72–11.04)

Period of COVID-19 diagnosis
Jan–Apr 2020

Ref

Ref

Ref

-

May–Aug 2020

1.21 (1.04–1.40)

1.07 (0.90–1.27)

1.62 (1.15–2.29)

-

Sept–Dec 2020

0.87 (0.72–1.05)

1.04 (0.85–1.29)

0.33 (0.17–0.67)

-

Jan–Apr 2021

0.67 (0.54–0.83)

0.73 (0.58–0.93)

0.32 (0.15–0.69)b

-

May–Jun 2021

0.96 (0.48–1.93)

1.05 (0.48–2.29)

-

-

Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplant; NED, no evidence of disease.
a

Only linear term is included in the multivariable model.

b

Comparison group: Jan–Jun 2021 vs Jan–Apr 2020.

transplantation, the cumulative incidence of coinfections was
27% [14]. Most immunosuppressed patients receive empiric antibacterial or antifungal agents, which can lead to high costs,
side effects, drug–drug interactions, and development of resistance. In a previous report from Europe, North America, and
South America, >80% of patients with cancer and COVID-19
received empiric antimicrobials, although only 8% had another
infection at the time of COVID-19 diagnosis, and 19% developed secondary infections [9].
To our knowledge, this is the largest study of coinfections
among patients with cancer and COVID-19 to date. Coinfections
were reported in 17% of patients with cancer and COVID-19.
This proportion is higher than that captured in the general population [7], but still relatively low, and similar to that of a previous report [9]. In that series, most coinfections were bacterial
and associated with high CRP levels and increased mortality, in
agreement with our results.
Our findings and those of Gudiol et al. indicate that
most patients with cancer and COVID-19 do not develop
coinfections [9]. However, the high mortality rates associated
with coinfections in both reports call for early diagnosis and
treatment. Also, like COVID-19 itself, bacterial and fungal infections can add indirectly to cancer-attributable morbidity
and mortality by delaying the administration of potentially lifesaving chemotherapy [8]. Thus, we identified clinical parameters (older age, male sex, diabetes, pulmonary, cardiovascular,
or renal comorbid conditions, baseline corticosteroids, cytotoxic chemotherapy, performance status, hematologic or multiple malignancies, progressing cancer) and laboratory values
(CRP, neutrophil count) that could be useful for risk stratification. For example, neutropenic patients who have received
recent cytotoxic chemotherapy or tocilizumab could benefit
from preemptive protocols including serial (eg, weekly or twice
6 • OFID • Satyanarayana et al

weekly) testing of fungal markers and early administration of
antifungal agents in the setting of worsening pneumonia or
sepsis, taking into account regional and institutional epidemiological data.
Given that many factors associated with coinfection were
also associated with adverse COVID-19 outcomes in prior
studies (eg, older age, male sex, comorbidities), it is likely that
coinfections are an important mediator of adverse outcome
[15, 16]. However, lymphopenia was not associated with risk
of coinfection, although it was strongly associated with severe
illness and mortality in previous CCC19 studies [15, 16]. The
results of this report merit further external validation and may
help develop predictive models to guide timely and appropriate use of antibiotics and promote effective antimicrobial
stewardship.
With the large number of mucormycosis cases observed
during the SARS-CoV-2 surge in India, post-COVID-19 fungal
infections have emerged as an important category of highly
lethal coinfections [17]. The fungal syndrome that has been
best described is COVID-19-associated pulmonary aspergillosis (CAPA), with small case series reporting frequencies of
20%–30% among patients with severe COVID-19 [18–20].
Unlike post-COVID-19 mucormycosis, where >90% of cases
are proven, most cases of CAPA are classified as probable/putative [17, 18]. Notably, a series of postmortem cases and 1
recent systematic review of autopsy data indicate that many
cases classified as CAPA reflect colonization with Aspergillus,
as proven invasive mold disease was rare (0%–2%), even when
studied only among patients with severe COVID-19 who died
[21, 22].
Our results support the notion that COVID-19-associated
fungal coinfections are rare, as their prevalence was only 0.9%.
Likewise, Saade et al. reported only 1 fungal infection among
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Tocilizumab

Total surveys submitted:
12 034
Test cases excluded: 134
Case records:
11 900
Screen failuresa excluded:
195

Incomplete records excluded:
1050
10 655
Screen failures manuallyb
excluded: 285
10 370
Records started after 6/6/21: 62
Reports at data lock:
10 308
QS >4 or non-laboratory
-confirmed:980
9328
<18 years-old: 21
9307
Unknown infection status
or 30-day mortality: 542
Total reports in the study: 8765
Hospitalized: 4508
Outpatients: 4199
Unknown hospitalization status: 58

Figure 1. Descriptive flowchart of patients included in the study. aNonmelanoma
skin cancers, in situ malignancies, or premalignant conditions. bDuplicate records, noninvasive malignancies, precursor or benign hematologic conditions,
presumed false-positive SARS-CoV-2 test results, low QS from a non-CCC19 site.
Abbreviations: CCC19, COVID-19 and Cancer Consortium; QS, quality score; SARSCoV-2, severe acute respiratory syndrome coronavirus 2.

100 patients with cancer or organ transplantation and COVID19, and Gudiol et al. found that only 1% of all patients with
cancer and COVID-19 developed opportunistic infections;
fungal pneumonia was the only fungal infection reported in 3
patients (<0.5%) [9, 14]. We acknowledge that diagnosis of invasive fungal infections is elusive, and some cases may not have
been captured, especially given the 2-week time frame and long
incubation times of mold infections [23]. Unlike some other cohorts, we do not know of standardized diagnostic protocols and
surveillance for CAPA across different centers participating in
CCC19 [24, 25]. However, these caveats could have been offset
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by the significant number of patients at risk for invasive fungal
infections in our report, such as those with neutropenia (8.7%
of patients with coinfections) (Supplementary Table 1) or receiving corticosteroids (36.3% of patients with coinfections)
(Table 1).
Neutropenia exhibited a strong association with elevated risk
of fungal infections, although it has been suggested that CAPA
frequently occurs in atypical, immunocompetent (before diagnosis of SARS-CoV-2 infection) hosts with critical COVID-19
[18–20]. Interestingly, the strong association between fungal
coinfection and receipt of cytotoxic chemotherapy within 4
weeks to 3 months before diagnosis of COVID-19 is aligned
with the incubation period for most invasive fungal infections.
Overall, our results further highlight the need for antifungal
stewardship and prospective, carefully designed studies with
tissue diagnoses to better define the epidemiology and clinical
features of CAPA and other post-COVID-19 fungal infections
[18].
The role of immunomodulating treatments among patients
with COVID-19 who already have impaired immune systems remains controversial. Corticosteroids are currently the
standard of care for hospitalized patients who require O2 supplementation based on the results from the RECOVERY trial,
which showed mortality benefit from dexamethasone, compared with controls [26]. In a previous observational study of
patients with cancer, we did not find a significant 30-day mortality benefit from corticosteroids, which, nonetheless, were
often administered to severely ill patients and combined with
other treatments [27]. Broad use of corticosteroids has been
implicated in outbreaks of post-COVID-19 mucormycosis: in
1 systematic review, 88% of patients with mucormycosis were
receiving systemic steroids [17]. In another recent study, dexamethasone use was significantly associated with coinfections
[14]. We found that patients receiving baseline corticosteroids
(at the time of COVID-19 diagnosis, previously prescribed for
reasons other than COVID-19 treatment) were at higher risk
of coinfection after adjustment for other factors. Therefore, in
such patients, early administration of antimicrobials, along with
a thorough diagnostic workup and ongoing assessment for infection, is advisable.
We did not study the potential association of corticosteroid
use as treatment for COVID-19 with coinfection, as we did not
have event dates. However, we analyzed the relationship between
administration of tocilizumab and presumably superinfection,
as clinical suspicion of an active, preexisting bacterial, viral, or
fungal coinfection precludes tocilizumab administration [11].
We found a strong association between tocilizumab use and development of any, bacterial, or fungal superinfections. Although
residual confounding from unmeasured factors associated with
critical illness and high oxygen requirements among patients
who received tocilizumab is possible, our findings support the

Coinfection

Bacterial

0.25

1

Viral

Fungal

Diabetes mellitus
(yes vs no)
Pulmonary comorbidities
(yes vs no)

Recent cytotoxic chemotherapy
(yes vs no)
Baseline corticosteroids
(yes vs no)
Tocilizumab
(yes vs no)
0.5

2
Odds ratio

4

8

Figure 2. Forest plot of categorical clinical variables significantly associated with at least ≥1 coinfection category (bacterial, viral, or fungal). Recent cytotoxic chemotherapy is that received between 4 weeks and 3 months from the date of COVID-19 diagnosis. Abbreviation: COVID-19, coronavirus disease 2019.

current recommendation that IL6 inhibitors should be used
with caution in immunocompromised patients [28].
Limitations of this study include retrospective data collection
in many cases, potential ascertainment bias, limited granularity
for specific pathogens and comorbid conditions, dependence
on clinically annotated data with reliance on abstractor judgment, and use of time intervals rather than specific dates to
ensure de-identified data. Also, we could not differentiate infections present at the time of COVID-19 diagnosis from nosocomial superinfections, which likely represent most coinfections

30-day mortality

Yes

No

No coinfection
(9.4%)

34.2%
24.6%

Bacterial

22.9%

Viral Fungal
Coinfection type

24.2%

Not classified

Figure 3. Thirty-day all-cause mortality by coinfection type. The width of the
boxes is proportional to the number of coinfections; the height of the boxes is proportional to the number of patients who died or did not die within 30 days.
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among patients with COVID-19. We had no information regarding timing of corticosteroid administration as treatment
for COVID-19 due to the survey design. Last, different and
evolving institutional standards in diagnosing and reporting
bacterial, viral, or fungal infections may account for the observed associations of coinfections with specific geographic regions and time periods.
While the above can be considered important limitations,
this study represents a large multi-institutional effort subject to the realistic constraints of voluntary data reporting. Its
strengths include the large number of patient records, allowing
adjustments for multiple confounders, a comprehensive list of
demographic, clinical, and laboratory variables, and a robust
quality assurance process.
In conclusion, the frequency of coinfections among patients
with cancer and COVID-19 in our study was relatively low
but not trivial. Viral and fungal coinfections were uncommon.
Coinfections were associated with high mortality rates. The use
of tocilizumab in immunocompromised patients with cancer
and COVID-19 may increase their risk of developing secondary infections. Several clinical and laboratory parameters
could guide early empiric antimicrobial agent selection, which
may improve clinical outcomes. These data could inform antimicrobial stewardship interventions in this tenuous patient
population.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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Hematological neoplasm
(vs solid tumor)

Table 3.

Univariable and Adjusted Associations Between Coinfections and Mortality
Unadjusted 30-Day Mortalitya
Coinfection, No. (%)

No Coinfection, No. (%)

Adjustedb OR (95% CI)

P Value

347/1459 (23.8)

689/7306 (9.4)

1.77 (1.50–2.08)

<.001

Bacterial

261/1062 (24.6)

775/7703 (10.1)

1.61 (1.33–1.95)

<.001

43/188 (22.9)

993/8577 (11.6)

1.48 (0.99–2.21)

.058

27/79 (34.2)

1009/8686 (11.6)

2.20 (1.28–3.76)

.004

136/563 (24.2)

900/8202 (11.0)

1.14 (0.89–1.47)

.293

Viral
Fungal
Not classified

Abbreviations: COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; HCT, hematopoietic cell transplant; OR, odds ratio.
a

Number with 30-day mortality/No. with (yes/no) coinfection (%).

b

For age, sex, race, region, comorbidities (cardiovascular, pulmonary, renal disease, diabetes), ECOG Performance Status, type of malignancy, cancer status, HCT, recent cytotoxic chemotherapy, corticosteroids at any time, tocilizumab, period of COVID-19 diagnosis.
c

The C-statistic of the model with any concomitant infection is 0.834.
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